STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts

STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts - WuXi Biology

Access Resources

Thank you for your interest in our resources. Please fill out the information here to have full access to our library of useful information, including what you are looking for currently.

Name(Required)

Work Email(Required)

Company(Required)

Your Region(Required)

Your Country

U.S. State

European Country

This field is hidden when viewing the form

Your Country

This field is hidden when viewing the form

U.S. State

This field is hidden when viewing the form

Territory

← Return to Resources

Related Content

Development of the Venetoclax-Resistant AML Model

Acute myeloid leukemia (AML) remains a highly aggressive hematologic malignancy, responsible for over 100,000 deaths globally each year. The approval...

VIEW RESOURCE

AACR 2026 Posters: Sneak Peek

AACR 2026 Posters | Sneak Peek The Annual Meeting of the American Association for Cancer Research (AACR) will be held...

VIEW RESOURCE

← View all Oncology Resources

×

Access Resources

Related Content

Development of the Venetoclax-Resistant AML Model

AACR 2026 Posters: Sneak Peek

Contact An Expert Today!